Clinical trial
Risperidone Augmentation in Patients With Schizophrenia
NCT00289861 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00289861 |
|---|---|
| Title | Risperidone Augmentation in Patients With Schizophrenia |
| Official title | Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Risperidone, placebo |
| Enrollment | 24 |
| Start date | Feb 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Feb 10, 2006 |
| Last update posted | Oct 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: